Posted by Questionmark on April 24, 2003, at 20:58:19
In reply to Re: What SDRI is currently on the market? Some..., posted by garylee on April 24, 2003, at 20:10:58
> extract from: http://www.acnp.org/g4/GN401000115/CH113.html
>
> "Effect of DA Agonists on Negative Symptoms
>
> If negative symptoms were related to decreased function of the mesocortical DA system, one would expect treatment with DA agonists to improve negative symptoms of schizophrenia. Various studies have attempted to improve schizophrenic symptoms by increasing DA activity. Most have failed to find clinically meaningful effects (see ref. 38). However, recently the DA reuptake inhibitor, mazindole (2 mg/day), improved negative symptoms as compared to placebo (39). In that study, mazindole or placebo were added to neuroleptic treatment after patients had been stabilized on neuroleptic for 4 weeks. However, well-controlled large studies are needed to explore the efficacy of increasing DA activity in the negative symptoms of schizophrenia, although the data reviewed here certainly encourage such an approach. "
>
>
> Amineptine IS on the market - in Brazil... It's manufactured by Servier Brazil. I have spoke with them and confirmed that it is still in production, under the original brand name Survector.Alright, wait a minute now. What the heck? Does anything make sense?!
They use DA antagonists to reduce the positive symptoms of schizophrenia and now they're using DA agonists to reduce the negative symptoms?? i'm sorry, but how the **** does that work? These doctors think they know what they're doing but they barely have a freaking clue. We don't know what's going on. We think we know how things work but we don't.
i really feel bad for the schizophrenics. They must have it especially bad. i can't imagine..
God help them. and all of us. please. i hope.
poster:Questionmark
thread:221618
URL: http://www.dr-bob.org/babble/20030423/msgs/222144.html